Clinical Trial Update: Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for RO4929097, a gamma secretase inhibitor, in patients with previously treated metastatic pancreatic cancer. The study has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-11-26